Special Issues
Table of Content

The Metabolic Reprogramming and Its Intervention in Tumorigenesis

Submission Deadline: 01 April 2025 (closed) View: 554 Submit to Journal

Guest Editors

Yuseok Moon, Pusan National University, Korea. E-mail: muconetworklab@gmail.com
Arulkumar Nagappan, Pusan national university, Korea. E-mail: arulbiotechtnau@gmail.com


Summary

This issue aims to explore the critical role of metabolic reprogramming in cancer stemness, development, progression, and microenvironment. Metabolic reprogramming, characterized by one representative feature of the cellular shift from oxidative phosphorylation to glycolysis even in the presence of oxygen (the Warburg effect), has been considered a hallmark of cancer, but there is huge heterogeneity in the metabolic shifts. This metabolic switch supports the rapid proliferation and chemoresistance of tumor cells by supplying necessary biosynthetic intermediates, maintaining redox balance, and creating an acidic microenvironment conducive to invasion and metastasis. The intricate or external factors driving this reprogramming or its interventions are of significant interest in the cancer research community. We seek manuscripts that delve into the molecular and cellular mechanisms underlying metabolic reprogramming and intervention in cancer. 


Topics of interest include but are not limited to: 

· Molecular Drivers of Metabolic Reprogramming and Plasticity 

· Therapeutic or Preventive Strategies Targeting Metabolic Reprogramming and Plasticity 

· Tumor Niche, Stemness, and Metabolic Interplay 

· Any other Challenges and Future Directions on addressing tumor heterogeneity and 

metabolic plasticity in therapy resistance, identifying biomarkers for predicting tumor metabolic phenotypes and treatment responses, and innovations in personalized metabolic therapies tailored to individual tumors.


Keywords

Metabolic Reprogramming, Plasticity, Mitochondria, Cancer Stemness, Therapeutic Interventions, Chemoresistance, Tumor Microenvironment, Tumor stemness, Chemoprevention

Published Papers


  • Open Access

    ARTICLE

    P2RX1 Influences the Prognosis of Ph+/Ph-Like ALL through Energy and Calcium Metabolism

    Xiangmei Ye, Baoyi Yang, Xin Zhang, Luyuan Yang, Likun Zhang, Qin Ren, Xiaobing Li, Leiguang Feng, Lanlan Wei, Peng Song, Yuqing Ye, Xin Lian, Yujuan Gao, Haidi Tang, Zhiyu Liu
    Oncology Research, DOI:10.32604/or.2025.068814
    (This article belongs to the Special Issue: The Metabolic Reprogramming and Its Intervention in Tumorigenesis)
    Abstract Objectives: Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia and Philadelphia-like B-cell acute lymphoblastic leukemia (Ph+/Ph-like ALL) constitute the majority of relapsed/refractory B-ALL (R/R B-ALL) cases, highlighting an urgent need to discover new therapeutic targets. This study aims to elucidate the mechanisms underlying poor prognosis in Ph+/Ph-like ALL through transcriptome sequencing and functional cytological assays, with the goal of informing new clinical treatment strategies. Results: Transcriptomic analysis of Ph+/Ph-like ALL patients revealed that low expression of P2X Purinoceptor 1 (P2RX1) was associated with unfavorable outcomes. Specifically, patients with poor prognosis and low P2RX1 expression exhibited downregulation of… More >

Share Link